Type I Hypersensitivity Completed Phase 3 Trials for Tyrosine (DB00135)

Back to Type I Hypersensitivity

Also known as: Immediate Hypersensitivity / Hypersensitivity, Immediate / Immediate Type Hypersensitivity / Immediate hypersensitivity reaction / Immediate hypersensitivity reactions / Allergen-mediated IgE Allergy / Immediate hypersensitivity (disorder) / Hypersensitivity type I / Hypersensitivity type I NOS / Immunoglobulin E-mediated allergic disorder (disorder)

Indication	Status	Phase
DBCOND0030618 (Type I Hypersensitivity)	Completed	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00414141	Efficacy and Safety/Tolerability of Grass MATA MPL	Treatment	Tyrosine (DB00135)